CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies

Bibliography

• Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway–beyond rapalogs. Oncotarget 2010;1(7):530-43
   PubMedGoogle Scholar
• Reif K, Okkenhaug K, Sasaki T, Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 2004;173(4):2236-40
   PubMed Web of Science ®Google Scholar
• Saudemont A, Garcon F, Yadi H, p110gamma and p110delta isoforms of phosphoinositide 3-kinase differentially regulate natural killer cell migration in health and disease. Proc Natl Acad Sci USA 2009;106(14):5795-800
   PubMed Web of Science ®Google Scholar
• Borlado LR, Redondo C, Alvarez B, Increased phosphoinositide 3-kinase activity induces a lymphoproliferative disorder and contributes to tumor generation in vivo. FASEB J 2000;14(7):895-903
   PubMed Web of Science ®Google Scholar
• Chantry D, Vojtek A, Kashishian A, p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272(31):19236-41
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Welham MJ, Kotani K, P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997;94(9):4330-5
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116(12):2078-88
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010;116(9):1460-8
   PubMed Web of Science ®Google Scholar
• Uddin S, Hussain AR, Siraj AK, Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006;108(13):4178-86
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Hansson U, Olsson M, High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Br J Haematol 2010;149(4):560-8
   PubMed Web of Science ®Google Scholar
• Rudelius M, Pittaluga S, Nishizuka S, Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006;108(5):1668-76
   PubMed Web of Science ®Google Scholar
• Garcia-Martinez JM, Wullschleger S, Preston G, Effect of PI3K- and mTOR-specific inhibitors on spontaneous B-cell follicular lymphomas in PTEN/LKB1-deficient mice. Br J Cancer 2011;104(7):1116-25
   PubMed Web of Science ®Google Scholar
• Renne C, Willenbrock K, Martin-Subero JI, High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 2007;21(4):780-7
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117(2):591-4
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011
   PubMedGoogle Scholar
• Herman SE, Lapalombella R, Gordon AL, The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011;117(16):4323-7
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Miller KC, Lawrence D, Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011;117(10):2127-35
   PubMed Web of Science ®Google Scholar
• Meadows SA, Kashishian A, Johnson D, CAL-101, a Potent selective inhibitor of the p110{delta} Isoform of Phosphatidylinositol 3-kinase, Attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. ASH Annual Meeting Abstracts 2010;116(21):3926
   Google Scholar
• Coutre SE, Byrd JC, Furman RR, Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110d, in patients with previously treated chronic lymphocytic leukemia. ASCO Meeting Abstracts 2011;29(15 Suppl):6631
   Google Scholar
• Furman RR, Byrd JC, Brown JR, CAL-101, An isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. ASH Annual Meeting Abstracts 2010;116(21):55
   Google Scholar
• Kahl B, Byrd JC, Flinn IW, Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, in patients with relapsed or refractory Non-Hodgkin lymphoma. ASH Annual Meeting Abstracts 2010;116(21):1777
   Google Scholar
• Flinn IW, Schreeder MT, Coutre SE, A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110{delta}, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies. ASCO Meeting Abstracts 2011;29(15 Suppl):3064
   Google Scholar
• Flinn IW, Schreeder MT, Wagner-Johnston N, A Phase 1 study of CAL-101, An isoform-selective inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, in combination with rituximab and/or bendamustine in patients with relapsed or refractory B-Cell malignancies. ASH Annual Meeting Abstracts 2010;116(21):2832
   Google Scholar
• An Extension Study for Patients Who Are Deriving Benefit With CAL-101 to Continue on Treatment at the End of the Current Study (101-99). ClinicalTrials.gov [website] Available from: http://clinicaltrials.gov/ct2/show/NCT01090414 [Accessed on 5 September 2011]
   Google Scholar
• Safety and Efficacy Study of CAL-101 in Patients With Previously Untreated Low-grade Lymphoma. ClinicalTrials.gov [website] Available from: http://clinicaltrials.gov/ct2/show/NCT01306643 [Accessed on 5 September 2011]
   Google Scholar
• Phase 2 Safety and Efficacy Study of CAL-101 (GS-1101) in Relapsed or Refractory Hodgkin Lymphoma. ClinicalTrials.gov [website] Available from: http://clinicaltrials.gov/ct2/show/NCT01393106 [Accessed on 5 Septmeber 2011]
   Google Scholar
• Efficacy and Safety Study of CAL-101 in Patients With Indolent B-Cell Non-Hodgkin Lymphoma (DELTA). ClinicalTrials.gov [website] Available from: http://clinicaltrials.gov/ct2/show/NCT01282424 [Accessed on 5 September 2011]
   Google Scholar
• A Study of CAL-101 and Rituximab in Elderly Patients With Untreated CLL or SLL (101-08). ClinicalTrials.gov [website] Available from: http://clinicaltrials.gov/ct2/show/NCT01203930 [Accessed on 5 September 2011]
   Google Scholar
• Study to Investigate CAL-101 in Combination With Chemotherapeutic Agents and CD20 mAb in Patients With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia. ClinicalTrials.gov [website] Available from: http://clinicaltrials.gov/ct2/show/NCT01088048 [Accessed on 5 September 2011]
   Google Scholar
• Feugier P, Van Hoof A, Sebban C, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23(18):4117-26
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7(5):379-91
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376(9747):1164-74
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Attal M, Avet-Loiseau H, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010;28(30):4621-9
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander NS, Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11(1):29-37
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363(19):1812-21
   PubMed Web of Science ®Google Scholar